Skip to main content

Northpond Ventures GP, LLC's Form 4 filing

Vigil Neuroscience, Inc.VIGL · filed Jan 11, 2022

Accession no.
0000899243-22-001631
Filed
Jan 11, 2022, 8:18 PM ET
Trade date
Jan 11, 2022
Filing delay
Same day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $4.97M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Northpond Ventures GP, LLCCIK 000186747010% Owner
Northpond Ventures, LPCIK 000186747210% Owner
Rubin Michael P.CIK 000186762710% Owner
Northpond Ventures II GP, LLCCIK 000186911410% Owner
Northpond Ventures II, LPCIK 000186912810% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 11, 2022Common StockCConversionAcquired+2,831,520–F1–2,831,520IndirectDuplicate filing
Jan 11, 2022Common StockCConversionAcquired+1,027,978–F1–1,027,978IndirectDuplicate filing
Jan 11, 2022Common StockPPurchaseAcquired+355,000$14.00+$4,970,0001,382,978Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 11, 2022Common StockCConversionDisposed−2,831,520–F1–0Indirect
Jan 11, 2022Common StockCConversionDisposed−1,027,978–F1–0Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the "Issuer"), each share of Series A Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the "Series B Preferred Stock") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date.

Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)